雷洛昔芬价格一览

Raloxifene is a selective estrogen receptor modulator indicated for postmenopausal osteoporosis and may reduce the risk of invasive breast cancer in high-risk women. The drug has been launched in China and is included in medical insurance. There are two options on the market: original drugs and generic drugs. The price of Eli Lilly's original drug Evista in the United States is about US$70 per box (60mg*100 tablets), while the price of generic drugs from Nippon Medical Industry Co., Ltd. is about US$42 per box. This article will comprehensively introduce the relevant information of raloxifene from three aspects: price comparison, treatment effect and medical insurance reimbursement.

Prices of Raloxifene original drug and generic drug

There are two choices of original drug and generic drug on the market, and the price difference is obvious. Understanding pricing information for different versions can help patients make cost-effective choices.

Original drug price

The original drug Evista produced by Eli Lilly and Company in the United States has a specification of 60mg*100 tablets/box and a price of approximately US$70. The research and development cost of original drugs is high and the quality is guaranteed, but the price is relatively expensive.

Price of generic drugs

The generic drugs produced by Nippon Medical Industry Co., Ltd. have the same specification of 60mg*100 tablets/box, and the price is about US$42. Generic drugs have obvious price advantages, providing patients with a more economical choice.

Original drugs and generic drugs have the same active ingredients, but there may be differences in production processes and excipients. Patients can choose the appropriate version based on their financial situation and doctor's recommendations.

The therapeutic effect of raloxifene

Raloxifene has a dual mechanism of action, which can not only improve bone density but also reduce the risk of breast cancer. Its clinical effects have been confirmed by multiple studies.

Osteoporosis treatment effect

Long-term use of raloxifene can significantly increase bone density and reduce the risk of vertebral fractures. It is recommended to supplement with calcium and vitamin D, and the daily intake of elemental calcium should reach 1500mg.

Breast cancer prevention effect

For high-risk postmenopausal women, raloxifene can reduce the risk of invasive breast cancer, but it should be noted that it is not suitable for treating breast cancer that has already occurred.

The dual therapeutic effect of raloxifene makes it an important choice for postmenopausal women to prevent osteoporosis and breast cancer, but the indications need to be strictly controlled.

Raloxifene’s medical insurance reimbursement situation

Raloxifene has been included in China’s medical insurance catalog, reducing the financial burden for patients. Understanding reimbursement policies can help you plan your treatment costs appropriately.

Medical insurance coverage

Raloxifene is included in the National Medical Insurance Category B Catalog. The reimbursement rate varies from region to region and must be purchased at designated medical institutions with a doctor's prescription.

Notes on reimbursement

Diagnosis certificate is required for reimbursement, and is limited to postmenopausal osteoporosis patients. Reimbursement in some areas may have specific requirements for drug brands. It is recommended to consult the local medical insurance department in advance.

Reimbursement by medical insurance has significantly reduced the cost of raloxifene treatment, allowing more patients to obtain this effective drug.